Fig. 1: Treatment protocol and phenotypic kinetics during the RESET therapy. | Blood Cancer Journal

Fig. 1: Treatment protocol and phenotypic kinetics during the RESET therapy.

From: Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity

Fig. 1

A Graphical representation of the treatment protocol and the timepoints selected for the analysis of patients’ peripheral blood immune profile. B Heatmap showing the CD38 mean fluorescence intensity (MFI) expression reduction due to Dara administration throughout the treatment period. Axis on the right depicts the MFI fold-change of CD38 expression on each immune subset when compared with the baseline levels. C Heatmap showing the relevant changes in the prevalence of various immune subsets during the treatment period. Color gradient highlights the fold-change differences in the abundance of each subset at any timepoint when compared with the baseline levels. # calculated as (%) of total nucleated cells ¥ calculated as (%) of total natural killer (NK) cells, € calculated as (%) of total CD8 + T cells, Dara daratumumab, eff. effector, IMiD immunomodulatory agent, PB peripheral blood, PD progressive disease, PI proteasome inhibitor, Tregs regulatory T cells. *p < 0.5; **p < 0.01; ***p < 0.001.

Back to article page